SCHEMBL5261685

SCHEMBL5261685

O=c1cc(N2CCOCC2)oc2c(-c3ccc(O)c(-c4ccccc4)c3)cccc12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 19/20 0.81
KDM4E B2RXH2 2/20 0.81
ALDH1A1 P00352 2/20 0.81
SMN1; SMN2 Q16637 2/20 0.81
PIK3CD O00329 1/20 0.81
PDE2A O00408 1/20 0.81
PIK3C2A O00443 1/20 0.81
PIK3R2 O00459 1/20 0.81
PIK3C2B O00750 1/20 0.81
BRD4 O60885 1/20 0.81
PDE5A O76074 1/20 0.81
TP53 P04637 1/20 0.81
CYP1A2 P05177 1/20 0.81
CYP3A4 P08684 1/20 0.81
CYP2D6 P10635 1/20 0.81
PIM1 P11309 1/20 0.81
CYP2C9 P11712 1/20 0.81
ALOX15 P16050 1/20 0.81
TSHR P16473 1/20 0.81
CSNK2A2 P19784 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ly-294002 SCHEMBL29424167 0.90 PRKDC (1.00) PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD
Ly-294002 SCHEMBL94377 0.90 PRKDC (1.00) PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD
Ly-294002 SCHEMBL5078472 0.89 ALDH1A1 (1.00) PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD
SCHEMBL13496867 0.89 PRKDC (0.97) PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD
SCHEMBL5260468 0.88 PRKDC (0.81) PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD
SCHEMBL31061281 0.87 PRKDC (1.00) PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD
SCHEMBL14041172 0.87 PRKDC (1.00) PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD
SCHEMBL5258643 0.86 PRKDC (1.00) PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD
SCHEMBL31061056 0.86 PRKDC (1.00) PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD
SCHEMBL4423159 0.83 PRKDC (0.81) PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869040-A1 DNA-PK INHIBITORS Kudos Pharmaceuticals Ltd (GB) 2007-12-26 EP disclosed
US-20060264623-A1 DNA-PK inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2006-11-23 US disclosed
WO-2006109084-A1 DNA-PK INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264623-A1 DNA-PK inhibitors TOP2B, TOP2A, POLN PRKDC 121/4885KDM4E 1505/4885ALDH1A1 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.